FDA grants RMAT status to Opus Genetics’ OPGx-LCA5 gene therapy
The US FDA has granted regenerative medicine advanced therapy (RMAT) designation to Opus Genetics’ gene therapy OPGx-LCA5
The US FDA has granted regenerative medicine advanced therapy (RMAT) designation to Opus Genetics’ gene therapy OPGx-LCA5
What's Your Reaction?
